Navigation Links
Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine

t to risks and uncertainties and, therefore, actual results may differ materially from those expressed or implied by these forward-looking statements. The reader

should not rely on any forward-looking statement. The Company undertakes no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise. Several important factors, in addition to the specific factors discussed in connection with these forward-looking statements individually, could affect the future results of Endo and could cause those results to differ materially from those expressed in the forward-looking statements contained in this press release. Important factors that may affect future results include, but are not limited to: market acceptance of the Company's products and the impact of competitive products and pricing; dependence on sole source suppliers; the success of the Company's product development activities and the timeliness with which regulatory authorizations and product launches may be achieved; successful compliance with extensive, costly, complex and evolving governmental regulations and restrictions; the availability on commercially reasonable terms of raw materials and other third party manufactured products; exposure to product liability and other lawsuits and contingencies; dependence on third party suppliers, distributors and collaboration partners; the ability to timely and cost effectively integrate acquisitions; uncertainty associated with pre-clinical studies and clinical trials and regulatory approval; uncertainty of market acceptance of new products; the difficulty of predicting FDA approvals; risks with respect to technology and product development; the effect of competing products and prices; uncertainties regarding intellectual property protection; uncertainties as to the outcome of litigation; changes in operating results; impact of competitive products and pricing; product development; changes in laws and re
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 Research ... of the "New EU Pharmacovigilance Legislation (London, UK ... The 15 new EU modules concerning ... way Pharmacovigilance is conducted in Europe ... at these modules and their requirements, examine how they ...
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... Companies" to their offering. This ... clinical specialty, aimed at improving patient care by ... adjust the dose of drugs for improving outcome. ...
(Date:9/2/2015)... CALABASAS, Calif. , Sept. 2, 2015 /PRNewswire/ ... on developing revolutionary therapies to treat severe neurological ... been dosed in its multi-center Phase 1/2a clinical ... type I (MPS I). AGT-181 ... the treatment of MPS I. The most severe ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
... 16, 2011 White Smile Global Inc. (OTCBB: WSML) ... update on the Company. Upon appointment of ... Giniger DMD, PhD, MsD, FICD, the Company has recently ... have been purchased in full from the world renowned Bio-Chemist. ...
... 2011 Healthcare Quality Catalyst Corp. ( www.hqcatalyst.com ), ... series of important events since September 2011 to continue ... SEQUOIA CAPITAL INVESTMENT ... announced the selection of Sequoia Capital as its investment ...
Cached Medicine Technology:White Smile Global Inc. Corporate Update on the White Smile Premier™ "At-Home" LED Teeth Whitening System and the White Smile Tooth Gloss™, Including Clinical Study, Product Manufacturing, and Distribution 2White Smile Global Inc. Corporate Update on the White Smile Premier™ "At-Home" LED Teeth Whitening System and the White Smile Tooth Gloss™, Including Clinical Study, Product Manufacturing, and Distribution 3Healthcare Quality Catalyst Partners With Sequoia, Adds Three Healthcare Veterans 2Healthcare Quality Catalyst Partners With Sequoia, Adds Three Healthcare Veterans 3Healthcare Quality Catalyst Partners With Sequoia, Adds Three Healthcare Veterans 4Healthcare Quality Catalyst Partners With Sequoia, Adds Three Healthcare Veterans 5
(Date:9/2/2015)... ... ... A recent survey by Consumer Reports ( http://bit.ly/1h67tL8 ) sheds light on ... consumers. It was reported that 33% are paying an average of $39 more out-of-pocket ... $100 compared to last year. Among the drugs that saw the highest increases were ...
(Date:9/2/2015)... ... September 02, 2015 , ... World ... Free Pocket Cop, a safety invention that protects people from crime and other ... billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing. "The ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... SERVICE GROUP is internationally known as an industry leader specializing in surplus used ... world, selling more than 100,000 pieces of medical equipment every year. Erik Tivin, ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to ... woman’s risk of getting ovarian cancer in her lifetime is approximately 1 in 75. ... of ovarian cancer, and 14,000 will die. , There is no test to ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... to bring awareness to International Overdose Awareness Day. The goal is to provide ... the warning signs so that they may get help. , Lakeview ...
Breaking Medicine News(10 mins):Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2
... Alcohol Provides Parents Resources to Help Manage Teen ... Access to Alcohol in the ... Alcohol today challenged New York area parents to take a tough,topic ... a roundtable discussion featuring a panel of experts from the fields,of ...
... to a study using a dynamic in vitro gastrointestinal ... SHQ) ulcerative colitis drug LIALDA (mesalamine) demonstrated a delivery ... 5-aminosalicyclic acid (5-ASA), is released over a prolonged period ... site of inflammation in ulcerative colitis. In this in ...
... any more sensitive in detecting biological motion compared with ... of Vision, an online, free-access publication of the Association ... Eric Hiris of St. Mary,s College of Maryland, (St ... on the subject begin with statements to the effect ...
... employee assistance,division of Recovery Resources Inc., is offering ... of October in,recognition of national Drug-Free Work Week ... an effective drug free workplace program. The ... 2007" in an,effort to educate businesses about the ...
... - With Photo - Business Executives Encouraged to ... Stroke and Funds for the Stroke Association Tom ... Olympic gold medallist, today launched ,Siemens Stroke for Stroke,Week, ... to,highlight the positive benefits of regular exercise and to ...
... New benefit offered to 10,000 Medicare Choice PPO members at no additional ... ... YORK, Oct. 17 Effective January 1, 2008, Group,Health Incorporated (GHI) has ... call a toll-free number to speak with,their own independent Personal Health Advocate ...
Cached Medicine News:Health News:Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking 2Health News:Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking 3Health News:Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking 4Health News:Parents Encouraged to Set an Example for Their Teens and Help Stop Underage Drinking 5Health News:LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon 2Health News:LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon 3Health News:AssistNow Offers Area Employers Complimentary Needs Assessment in Recognition of National Drug-Free Work Week 2Health News:James Cracknell Launches Siemens Stroke for Stroke Week 2Health News:James Cracknell Launches Siemens Stroke for Stroke Week 3Health News:James Cracknell Launches Siemens Stroke for Stroke Week 4Health News:GHI to Provide Independent Personal Health Advocate for Medicare Members 2
The ImagingPlanet 80 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 80 mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
The ImagingPlanet 55 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Zeiss surgical micro...
The ImagingPlanet 70 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Leica surgical micr...
... Archive Manage and ... ,Introducing Optronics DVMR- office, the ... designed for the physician's office ... a variety of high-resolution cameras ...
Medicine Products: